Experience

Regeneron

• United States
• Biotechnology
• 700 & Above Employee

• Associate Director, Clinical Sciences at Regeneron Pharma

  • Jun 2018 - Present

  Lead clinical development of the phase I/II/III protocols and study activities for several indications (Oncology/Hematology - r/r multiple myeloma, smoldering myeloma, MGUS_BCMAxCD3; COVID-19, Pain due to osteoarthritis) Lead clinical development of the phase I/II/III protocols and study activities for several indications (Oncology/Hematology - r/r multiple myeloma, smoldering myeloma, MGUS_BCMAxCD3; COVID-19, Pain due to osteoarthritis)



Merck

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Clinical Scientist/Assoc Director

  • Jun 2016 - Jun 2018

  Oncology/ Immuno-oncology (i-o): Phase II, III -Keytruda (pembrolizumab, PD-1 inhibitor), solid tumors/ adults Oncology/ Immuno-oncology (i-o): Phase II, III -Keytruda (pembrolizumab, PD-1 inhibitor), solid tumors/ adults



Novartis

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Clinical Manager

  • Mar 2013 - Jun 2016

  • Global Oncology Clinical Development, Phase I-III --March 2013 - March 2015: TKI Team: solid tumors, adults --March 2015 - June 2016: Gene&Cell Therapies Unit - (CART) Chimeric Antigen Receptor Adoptive T- cell therapy (immunotherapy) CTL019 Team: hematological malignancies - r/r acute leukemia (ALL), pediatric • Global Oncology Clinical Development, Phase I-III --March 2013 - March 2015: TKI Team: solid tumors, adults --March 2015 - June 2016: Gene&Cell Therapies Unit - (CART) Chimeric Antigen Receptor Adoptive T- cell therapy (immunotherapy) CTL019 Team: hematological malignancies - r/r acute leukemia (ALL), pediatric



Forest Laboratories (now Allergan)

• Pharmaceutical Manufacturing
• 500 - 600 Employee

• Clinical Scientist

  • Feb 2011 - Jan 2013

  • Clinical development and study management to provide scientific and logistical support to planned and ongoing CNS trials, Phase II, III; Regulatory submission for Cariprazine (schizophrenia) • Clinical development and study management to provide scientific and logistical support to planned and ongoing CNS trials, Phase II, III; Regulatory submission for Cariprazine (schizophrenia)



contract

• Quality Control (Document) Specialist

  • May 2010 - Jan 2011

  • Quality control and assurance; reviewing regulatory documentation (Trial Master File documents) related to the conduct of clinical trials for compliance with internal standards and GCP/ICH guidelines • Quality control and assurance; reviewing regulatory documentation (Trial Master File documents) related to the conduct of clinical trials for compliance with internal standards and GCP/ICH guidelines



GE HealthCare

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Clinical Research Associate (CRA) /Monitor

  • Sep 2009 - Sep 2010

  • Monitoring the study of investigational medical device for early detection of breast cancer in accordance with the Protocol and SOPs to insure the integrity per Protocol and GCP guidelines • Monitoring the study of investigational medical device for early detection of breast cancer in accordance with the Protocol and SOPs to insure the integrity per Protocol and GCP guidelines



Pharmaceutical strategic competitive intelligence firm

• Consultant/Analyst

  • 2008 - Mar 2010

  • Designed, managed and analyzed primary, as well as secondary research data to support business objectives and decision-making processes • Provided recommendations based on business implications of findings • Designed, managed and analyzed primary, as well as secondary research data to support business objectives and decision-making processes • Provided recommendations based on business implications of findings



CUNY School of Medicine

• United States
• Higher Education
• 400 - 500 Employee

• Research Scientist

  • Aug 2004 - 2008

  • Planned, managed and implemented research project’s activities to explore an anticancer mechanism of cholesterol-lowering drug Lovastatin (Mevacor) in non-small cell lung cancer • Assessed, analyzed and proactively developed experiments to elucidate the role of microRNAs in non-smal and small cell lung cancers • Planned, managed and implemented research project’s activities to explore an anticancer mechanism of cholesterol-lowering drug Lovastatin (Mevacor) in non-small cell lung cancer • Assessed, analyzed and proactively developed experiments to elucidate the role of microRNAs in non-smal and small cell lung cancers



Cornell University Weill Medical College

• New York, NY

• Research Scientist

  • Mar 2001 - Feb 2003

  • Conducted experiments to examine the regulation of Bruton's tyrosine kinase (Btk), the protein which genetic defects cause the human disease X-linked agammaglobulinemia (XLA) • Conducted experiments to examine the regulation of Bruton's tyrosine kinase (Btk), the protein which genetic defects cause the human disease X-linked agammaglobulinemia (XLA)



National Institute of Health (NIH)

• Research Scientist (post-doc)

  • Jan 1998 - Feb 2001

  • Carried out a project to identify the formation of a new complex between the wild-type human insulin receptor beta-subunit and molecule X, a thiol-reactive membrane-associated protein • Carried out a project to identify the formation of a new complex between the wild-type human insulin receptor beta-subunit and molecule X, a thiol-reactive membrane-associated protein